News

IDT Australia Completes CMAX Transaction

August 23, 2017

Australian pharmaceutical manufacturing and drug development company IDT Australia Limited (ASX: IDT) announces the final completion of the staged divestment of its CMAX clinical trial business to Japanese integrated healthcare company I’rom Group Co., Ltd (I’rom). IDT confirmsreceipt of $6,159,892 in cash for IDT’sremaining 39% stake in the CMAX business.  The final consideration payment increased from…

Read More »

IDT Australia launches new website

August 16, 2017

IDT Australia has today launched a newly responsive website created for use across mobile, tablet and desktop technologies. Retaining a quick “go-to” breakout investor section, the new site uses banner imagery and video to better showcase IDT’s award-winning API and ready for market manufacturing capabilities. “The IDT business continues to evolve, and today we offer…

Read More »

Dr Paul MacLeman resigns

August 9, 2017

The Managing Director of IDT, Dr Paul MacLeman has resigned from the position, to advance new business initiatives and to pursue further non‐executive board roles. His resignation as CEO will take effect from 31st August 2017. Dr MacLeman will resign from the Board as at close of business today. The Chairman, Mr Graeme Kaufman, thanked…

Read More »